The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

AML 43: Randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without glasdegib (pf-04449913) or azacitidine (aza) with or without glasdegib in patients with previously untreated acute myeloid leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

CLL 39: A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304.. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

CLL 44: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CLL 45: Previously Untreated Chronic Lymphocytic Leukemia (CLL): Debulking Regimens Prior to Initiating Venetoclax Combination Therapy in Frontline CLL Excluding 17p Deletion. PI: Dr Suman Kambhampati
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 120: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 122: A phase 3, randomized, double blind, placebo controlled, multicenter study of BR alone versus in combination with Acalabrutinib (ACP-196) in subjects with previously untreated mantle cell Lymphoma, radiologically measurable lymphadenopathy or extranodal lymphoid malignancy. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 126: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma. PI: Suman Kambhampati, MD
Facility: Menorah Medical Center, Research Medical Center

LYM 131: Phase 3 Study of Ibruinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma (MCL). PI: Suman Kambhampati, MD
Facility: Research Medical Center

LYM 132: A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kä Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 135: A phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of polatuzumab vedotin in combination with rituximab and chp (r-chp) versus rituximab and chop (r-chop) in previously untreated patients with diffuse large b-cell lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MDS 21: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

MM 74: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 99: A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 297: A phase III, multicenter, randomised, double-blind, placebo-controlled study of atezolizumab (anti-pd-l1 antibody) in combination with paclitaxel compared with placebo with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer. PI: Dr Stephanie Graff
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 298: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 302: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 303: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 304: A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer. PI: Dr Stephanie Graff
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 319: A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab in early her2-positive breast cancer (impassion050). PI: Dr Stephanie Graff
Facility: Menorah Medical Center

Amaze – SentreHeart: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Amulet – Abbott: Study to determine if Amulet device is safe and effective when compared to Watchman device. Randomized 1:1 Watchman vs Amulet. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

ASAP Too – Boston Scientific: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Yoaav Krauthammer
Facility: Overland Park Regional Medical Center, Research Medical Center

Diamond AF II – Epix: Evaluate the safety and effectiveness of the Diamond tipped catheter ablation system. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Node 301 – Milestone: Determine whether etripamil nasal spray 70 mg self-administered by patients is superior to placebo at terminating episodes of PSVT in an outpatient setting. This is a study that involves the patient coming back for a 2 hour Research visit at OPR. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Xe-POHCAS – Neuroprote Xeon Inc.: Evaluation on Days 30 and 90 post OHCA, whether there is a difference in functional outcome in comatose subjects who achieved ROSC within 30 minutes after OHCA and were treated with xenon 50% plus oxygen vs standard of care treatment without xenon during TTM. PI:Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

GI 245: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment ofFirst-Line Metastatic Pancreatic Cancer. PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GI 247: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer. PI: Jaswinder Singh, MD
Facility: Menorah Medical Center, Research Medical Center

GI 268: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locallyadvanced pancreatic adenocarcinoma. PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 118: An Open-Label, Non-randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY). PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 137: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 142: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GU 149: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 155: An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Dr Peter Van Veldhuizen
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 161: An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 166: A Phase 2, Randomized, Double-Blind, Placebo-ControlledStudy of Abiraterone Acetate plus Prednisone with or withoutAbemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Dr Peter Van Veldhuizen
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MULTI 26: A Phase II, Open-label, multicenter, multicohort study to investigate the efficacy and safety of Cobimetinib plus Atezolizumab in patient with solid tumors. PI: Peter Van Veldhuizen, MD
Facility: Menorah Medical Center, Research Medical Center

GYN 80: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer. PI: Kristopher LyBarger, DO
Facility: Menorah Medical Center, Research Medical Center

CNS 25: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradation and Adjuvant Temozolomide Chemotherapy. PI: Amandeep Kalra, MD
Facility: Research Medical Center

RM 365: A Phase Ib Study evaluating the c-Met Inhibitor INC280 in Combination with Bevacizumab in Glioblastoma Multiforme (GBM), Patients. PI: Amandeep Kalra, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 349: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU). PI: Joseph Stilwill, MD
Facility: Menorah Medical Center, Research Medical Center

LUN 380: A Phase II, Randomized, Blinded, Placebo-Controlled Study of MTIG7192A, an Anti-Tigit Antibody, in Combination with Atezolizumab in Chemotherapy-Naïve Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 384: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC). PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 385: A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients With Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center